Supernus Pharmaceuticals Inc (SUPN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

Total Revenue Chart for Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc (SUPN) revenue for FY2025 was USD 719.0M, a 8.6% change from FY2024. Supernus Pharmaceuticals Inc's revenue grew from USD 4.2M in 2007 to USD 719.0M in 2025 (16882.8% over 18 years). Earnings per share moved from USD -2.72 in 2012 to USD 0.98 in 2022. Revenue compound annual growth rate: 5-year CAGR of 6.7%, 10-year CAGR of 17.4%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$2.21B
Implied Share Price
$37.88
Enterprise Value
$2.19B
Revenue (TTM)
$830.44M
EBITDA
$110.43M
Profit Margin
-13.23%
Trailing P/E
—
Forward P/E
20.16
Price/Book (MRQ)
2.45
Price/Sales (TTM)
2.66
EV/EBITDA
51.86
EV/Revenue
2.64
Dividend Yield
—
Book Value
$17.73
Free Cash Flow (FY2025)
$45.99M
Free Cash Flow Yield
2.09%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.